Hippo pathway activated by circulating reactive oxygen species mediates cardiac diastolic dysfunction after acute

Xiao Han1, Quan Hong1, Fei Peng1

  • 1Department of Nephrology, First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Chinese PLA Institute of Nephrology, National Key Laboratory of Kidney Diseases, National Clinical Research Center for Chronic Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research, Beijing 100853, China.

Insights

Circulating reactive oxygen species (ROS) mediate cardiac dysfunction after acute kidney injury. ROS activate the Mst1/Hippo pathway, causing heart problems and offering new treatment targets for cardiorenal syndrome.

Area of Science:

  • Cardiology
  • Nephrology
  • Biochemistry

Background:

  • Acute kidney injury (AKI) can lead to cardiac dysfunction, but the mechanisms remain unclear.
  • Oxidative stress is implicated in cardiorenal interactions following AKI.

Purpose of the Study:

  • To investigate the role of circulating reactive oxygen species (ROS) in mediating cardiac dysfunction after renal ischemia-reperfusion injury (IRI).
  • To explore the involvement of the Mst1/Hippo pathway in this process.

Main Methods:

  • Induction of renal IRI in mice.
  • Assessment of cardiac function, oxidative stress, ATP levels, and branched-chain amino acid (BCAA) accumulation.
  • Treatment with tempol (ROS scavenger).
  • In vitro studies using Mst1-knockdown and Mst1-overexpression cardiomyocytes exposed to hydrogen peroxide (H2O2).

Main Results:

  • Renal IRI induced diastolic dysfunction, reduced cardiac ATP, increased oxidative stress, and BCAA accumulation.
  • Circulating ROS levels increased sequentially in kidneys, circulation, and heart.
  • Tempol treatment improved cardiac function and alleviated Mst1/Hippo pathway activation.
  • Mst1/Hippo pathway activation in cardiomyocytes was linked to oxidative stress and BCAA dysmetabolism.

Conclusions:

  • Circulating ROS following renal IRI activate the Mst1/Hippo pathway in the myocardium.
  • This activation leads to cardiac oxidative stress and diastolic dysfunction.
  • Findings suggest potential therapeutic strategies for cardiorenal syndrome targeting ROS and the Mst1/Hippo pathway.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422